Sirolimus [rapamycin; Wyeth-Ayerst] monotherapy to optimize activation induced cell death (AICD) in renal transplants following lymphocyte depletion induction with thymoglobulin [antithymocyte globulin; Sangstat].

Trial Profile

Sirolimus [rapamycin; Wyeth-Ayerst] monotherapy to optimize activation induced cell death (AICD) in renal transplants following lymphocyte depletion induction with thymoglobulin [antithymocyte globulin; Sangstat].

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2010

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Sirolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jun 2010 Actual patient numbers amended from 18 to 12 as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Patient numbers amended from 40 to 18 as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Actual end date (Dec 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top